Cure8 news brief
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming years if safety and effectiveness are confirmed.
Adult Crohn’s disease patients (including those with strictures or refractory disease), clinicians treating IBD, and researchers interested in biologics, combination therapy, and cellular immunotherapy.
TL1A inhibitors (examples named in the piece: telisucimab, duvacatug, afimicabab) are a highlighted drug class moving into phase 3 after encouraging phase 2 data; the article notes potential anti-fibrotic effects, which would be important because current therapies do not reliably reverse fibrosis.
The article describes combination approaches tested in trials (DUET-CD combining ustekinumab + golimumab; vedolizumab + upadacitinib is also being evaluated) and notes these aim to target two inflammatory pathways simultaneously for difficult-to-treat patients.
CAR-T cell therapy is presented as an early, investigational strategy to retrain the immune system; it is experimental and raises questions about safety, durability, and patient selection.
The piece is an expert overview based on phase 2 results, conference presentations, and ongoing trials; it is not a report of definitive phase 3 outcomes or approvals. CAR-T is at an early investigational stage and will require extensive study for safety and durability.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
